1616339-82-2 Usage
Uses
Used in Pharmaceutical Research and Development:
(2S,5R,13aS)-N-(4-fluorobenzyl)-8-hydroxy-7,9-dioxo-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide is used as a potential pharmaceutical candidate for various applications due to its complex structure and likely biological activity. Its unique molecular composition may offer novel therapeutic opportunities in the treatment of various diseases and conditions.
Used in Drug Design and Synthesis:
In the field of drug design and synthesis, (2S,5R,13aS)-N-(4-fluorobenzyl)-8-hydroxy-7,9-dioxo-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide can be used as a starting point for the development of new drugs. Its heterocyclic structure and functional groups may be modified to create a range of derivatives with different biological activities and properties, potentially leading to the discovery of new therapeutic agents.
Used in Chemical Synthesis and Material Science:
(2S,5R,13aS)-N-(4-fluorobenzyl)-8-hydroxy-7,9-dioxo-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide may also find applications in chemical synthesis and material science. Its unique structure and functional groups could be utilized in the development of new materials with specific properties, such as novel catalysts, sensors, or advanced materials for various industrial applications.
Check Digit Verification of cas no
The CAS Registry Mumber 1616339-82-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,6,1,6,3,3 and 9 respectively; the second part has 2 digits, 8 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1616339-82:
(9*1)+(8*6)+(7*1)+(6*6)+(5*3)+(4*3)+(3*9)+(2*8)+(1*2)=172
172 % 10 = 2
So 1616339-82-2 is a valid CAS Registry Number.
1616339-82-2Relevant academic research and scientific papers
POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE
-
Page/Page column 61-62, (2014/07/08)
Compounds for use in the treatment of human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, X, W, Y1, Y2, Ζ1 and Z4 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
